Nutrients, Vol. 18, Pages 366: Efficacy and Safety of Steamed Ginger Extract for Body Weight and Body Fat Reduction in Overweight Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Nutrients doi: 10.3390/nu18020366
Authors:
Jeong Eun Kwon
Yeong-Geun Lee
Inhye Kim
Jaewoo Bae
Se-Chan Kang
Hyang-Im Baek
Objective: This randomized, double-blind, placebo-controlled clinical trial assessed the efficacy and safety of steamed ginger extract (GGE03), standardized to high levels of 1-dehydro-6-gingerdione (GD), in reducing body fat and weight among overweight individuals. Methods: Eighty adults aged 18 to 60 years, with a body mass index (BMI) of 25.0 to 29.9 kg/m2, were randomly assigned to receive either GGE03 (n = 40; 480 mg/day) or a placebo (n = 40) for 12 weeks. Efficacy and safety parameters were evaluated at baseline and after the intervention period. Results: After 12 weeks, the GGE03 group showed statistically significant reductions in body fat percentage and body fat mass compared to the placebo group, as measured by dual-energy X-ray absorptiometry (DEXA). Additionally, significant decreases in body weight, BMI, waist circumference, and hip circumference were observed following GGE03 supplementation. Serum triglyceride (TG) and total cholesterol (TC) levels were also significantly lower in the GGE03 group compared to the placebo group. No product-related adverse events or clinically significant laboratory abnormalities were noted, indicating that GGE03 was well tolerated. Conclusions: Twelve weeks of GGE03 supplementation were associated with statistically significant improvements in body composition and lipid parameters without safety concerns. These findings support the potential of GD-standardized GGE03 as a well-tolerated functional dietary ingredient for body fat management and metabolic health.
Objective: This randomized, double-blind, placebo-controlled clinical trial assessed the efficacy and safety of steamed ginger extract (GGE03), standardized to high levels of 1-dehydro-6-gingerdione (GD), in reducing body fat and weight among overweight individuals. Methods: Eighty adults aged 18 to 60 years, with a body mass index (BMI) of 25.0 to 29.9 kg/m2, were randomly assigned to receive either GGE03 (n = 40; 480 mg/day) or a placebo (n = 40) for 12 weeks. Efficacy and safety parameters were evaluated at baseline and after the intervention period. Results: After 12 weeks, the GGE03 group showed statistically significant reductions in body fat percentage and body fat mass compared to the placebo group, as measured by dual-energy X-ray absorptiometry (DEXA). Additionally, significant decreases in body weight, BMI, waist circumference, and hip circumference were observed following GGE03 supplementation. Serum triglyceride (TG) and total cholesterol (TC) levels were also significantly lower in the GGE03 group compared to the placebo group. No product-related adverse events or clinically significant laboratory abnormalities were noted, indicating that GGE03 was well tolerated. Conclusions: Twelve weeks of GGE03 supplementation were associated with statistically significant improvements in body composition and lipid parameters without safety concerns. These findings support the potential of GD-standardized GGE03 as a well-tolerated functional dietary ingredient for body fat management and metabolic health. Read More